Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis
Authors:
- Andrew H. LimperALAndrew H. Limper
- Sanjay KalraSKSanjay Kalra
- Ulrich SpecksUSUlrich Specks
- John P. ScottJSJohn P. Scott
- Zvezdana Vuk-PavlovicZVZvezdana Vuk-Pavlovic
- Darrell R. SchroederDSDarrell R. Schroeder
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- The Gene Polymorphism of Tumor Necrosis Factor-β, But Not That of Tumor Necrosis Factor-α, Is Associated With the Prognosis of SarcoidosisChest, 2001
- POLYMORPHISMS AT POSITION −308 IN THE PROMOTER REGION OF THE TNF-α AND IN THE FIRST INTRON OF THE TNF-β GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-α RELEASE IN SARCOIDOSISCytokine, 1999
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- PATHOLOGY OF SARCOIDOSISClinics in Chest Medicine, 1997
- IMMUNOLOGY OF SARCOIDOSISClinics in Chest Medicine, 1997
- TUMOUR NECROSIS FACTOR ALPHA PROMOTER GENE POLYMORPHISM IN SARCOIDOSISCytokine, 1997
- OXPENTIFYLLINE IN ENDOTOXAEMIAThe Lancet, 1989
- The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infectionCell, 1989
- Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 yearsThe American Journal of Medicine, 1985